Preview

Medical alphabet

Advanced search

Cytokine clusters in rheumatoid arthritis: pathogenetic parallels

https://doi.org/10.33667/2078-5631-2026-12-38-44

Abstract

An imbalance in the production of pro- and anti-inflammatory cytokines plays a significant role in the pathogenesis of rheumatoid arthritis (RA). Seropositivity for IgM rheumatoid factor (RF) and/or antibodies to cyclic citrullinated peptides (ACCP) determines disease subtypes. The aim of the study. To conduct a cluster analysis of the profile of pro- and anti-inflammatory cytokines detected in the blood serum of RA patients with an advanced stage of the disease in comparison with healthy individuals, the presence of IgM RF and ACCP in patients. Materials and methods. The study included 154 RA patients (41 men and 113 women of middle age 56.0 [50.0; 64.0] years), disease duration 9.4 [3.0; 13.0] years), seropositive 129 (83.8 %) for IgM RF and/or 106 (68.8 %) ACCP with moderate or high (DAS 28-ESR – 5.40 [4.65; 6.00]) disease activity. Serum concentrations of interleukins (IL), tumor necrosis factor α (TNF-α), interferon-γ (INF-γ) and soluble CD 40 ligand (sCD 40L) were determined using multiplex technology. Hierarchical clustering of cytokines was performed in 20 healthy individuals and RA patients using Ward’s method. In RA, a comparison was made between seronegative and seropositive groups for IgM RF/ACCP. Results. In healthy individuals, the cytokine network exhibited a physiological organization. Cytokines were grouped into compact, well-defined modules with minimal cross-links between individual components. A dominant proinflammatory core of cytokines was absent, and a balanced cytokine network was observed. IL-4 and IL-10 formed an integral and stable part of the regulatory component. In RA, the cytokine network underwent a dramatic reorganization caused by systemic inflammation. The network architecture became significantly more complex and fragmented, with the formation of four highly stable modules. The first was composed of IL-1β and TNF-α; the second included the cytokines of the IL-17A, IL-17F, and IL-23 axis; the third included IL-6 and IFN-γ; and the fourth included IL-4, IL-10, IL-31, IL-33, and sCD 40L. Analysis of the cytokine hyperproduction diagram revealed the IL-33 cluster. In patients seronegative for IgM RF, four modules are formed. The first is formed by IL-17A, IL-23, IL-25, and IL-17F; the second by IL-1β and IFN-γ; the third includes IL-33, IL-6, and IL-10; and the fourth includes TNF-α, IL-31, sCD 40L, and IL-4. In the IgM RF-seropositive variant of RA, the network architecture became significantly more complex and fragmented. A greater number of modules were identified. The first was formed by IL-23 and IL-17F; the second by IL-1β, IL-25, and IL-17A. TNF-α was embedded in each of them. The third module included IFN-γ and IL-6, the fourth – IL-31 and sCD 40L, the fifth – IL-33 and IL-4. IL-10 is more similar to the first two. In the patient groups with and without ACCP, the component architecture was similar for both the seronegative and IgM RF-seropositive variants of the disease, with minimal differences. The most pronounced and clear differences between the compared groups were obtained when analyzing the patient groups with and without IgM RF and/or ACCP. Conclusions. The results of cluster analysis demonstrate significant differences in the cytokine network architecture in RA compared to the control group, with the identification of a distinct IL-33 cluster. Differences are also observed between seronegative and seropositive subtypes of the disease.

About the Authors

A. A. Baranov
Yaroslavl State Medical University
Russian Federation

Baranov Andrey A., Dr Med Sci (habil.), professor, head of Dept Outpatient Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry.



N. A. Lapkina
Yaroslavl State Medical University
Russian Federation

Lapkina Natalia A., PhD Med Sci, associate professor at Dept Outpatient Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry.



L. B. Shubin
Yaroslavl State Medical University
Russian Federation

Shubin Leonid B., PhD Med Sci, associate professor at Dept Public Health and Healthcare.



I. M. Vorontsova
Yaroslavl State Medical University
Russian Federation

Vorontsova Inessa M., PhD Med Sci, associate professor at Dept Outpatient Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry.



P. A. Chizhov
Yaroslavl State Medical University
Russian Federation

Chizhov Petr A., Dr Med Sci (habil.), professor at Dept of Faculty Therapy.



O. V. Lebedev
Yaroslavl State Medical University
Russian Federation

Lebedev Oleg V., PhD Med Sci, head at Base Dept in Kostroma, deputy chief physician for Medical Part No 2.



T. A. Buydina
Yaroslavl State Medical University
Russian Federation

Buydina Tatyana A., PhD Med Sci, associate professor at Dept Outpatient Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry



E. V. Nikitina
Yaroslavl State Medical University
Russian Federation

Nikitina Elena V., employee at Dept Outpatient Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry Department.



I. A. Gorohov
Yaroslavl State Medical University
Russian Federation

Gorohov Ivan A., resident at Dept of Traumatology and Orthopedics



References

1. Clinical recommendations «Rheumatoid arthritis». Website of the Ministry of Health of the Russian Federation, rubricator of clinical recommendations. (In Russ.). https://cr.minzdrav.gov.ru/view-cr/250_3 (дата обращения: 11.03.2026).

2. Nasonov E. L. Modern concept of autoimmunity in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023; 61 (4): 397–420. (In Russ.). DOI: 10.47360/1995-4484-2023-397-420

3. Gao Y, Zhang Y, Liu X. Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm. 2024; 5 (3): e509. DOI: 10.1002/mco2.509

4. Cheng X, Meng X, Chen R, Song Z, Li S, Wei S. et al. The molecular subtypes of autoimmune diseases. Comput Struct Biotechnol J. 2024; 23: 1348–1363. DOI: 10.1016/j.csbj.2024.03.026

5. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P. et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018; 4: 18001. DOI: 10.1038/nrdp.2018.1

6. Avdeeva A. S., Cherkasova M. V., Nasonov E. L. Different clinical relevance of anti-citrullinated proteins antibodies in RA patients. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022; 60 (2): 181–187. (In Russ.). DOI: 10.47360/1995-4484-2022-181-187

7. Gravallese EM, Firestein GS. Rheumatoid arthritis – Common origins, divergent mechanisms. N Engl J Med. 2023; 388 (6): 529–542. DOI: 10.1056/NEJMra2103726

8. Nasonov E. L., Avdeeva A. S., Dibrov D. A. Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023; 61 (3): 276–291. (In Russ.). DOI: 10.47360/1995-4484-2023-276-291

9. Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021; 22 (20): 10922. DOI: 10.3390/ijms222010922

10. Najm A, Ferguson LD, McInnes IB. Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis. Arthritis Rheumatol. 2025 Sep 9. DOI: 10.1002/art.43376

11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT. et al. 2010. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62 (9): 2569–81. DOI: 10.1002/art.27584

12. Dibrov D. A., Avdeeva A. S., Diatroptov M. E., Rybakova V. V., Nasonov E. L. Relation of cytokine profile and antibody values to post-translational protein modifications in patients with rheumatoid arthritis (preliminary data). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024; 62 (2): 186–191. (In Russ.). DOI: 10.47360/1995-4484-2024-186-191

13. Mars N, Kerola AM, Kauppi MJ, Pirinen M, Elonheimo O, Sokka-Isler T. Cluster analysis identifies unmet healthcare needs among patients with rheumatoid arthritis. Scand J Rheumatol. 2022; 51(5): 355–362. DOI: 10.1080/03009742.2021.1944306

14. Kalweit M, Burden AM, Boedecker J, Hügle T, Burkard T. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs. PLoS Comput Biol. 2023; 19 (6): e1011073. DOI: 10.1371/journal.pcbi.1011073

15. Sagawa F, Yamada H, Ayano M, Kimoto Y, Mitoma H. et al. Determination of the factors associated with antigen-specific CD 4+ T-cell responses to BNT162b2 in patients with rheumatoid arthritis. RMD Open. 2024; 10 (1): e003693. DOI: 10.1136/rmdopen-2023-003693

16. Lapkina N. A., Baranov A. A., Kolinko A. A., Abaytova N. E., Leontieva E. A. et al. Proin flammatory cytokines in rheumatoid arthritis: association with disease activity and subtypes. RMJ. 2024; 6: 47–51. (In Russ.).

17. Lapkina N. A., Baranov A. A., Vorontsova I. M., Konovalov K. M., Chizhov P. A., Lebe dev O. V., Buydina T. A. The main pro and antiinflammatory cytokines in rheumatoid arthritis: interrelationships and pathogenetic significance. Medical alphabet. 2024; (29): 68–74. (In Russ.). DOI: 10.33667/2078563120242968-74

18. Ouyang T, Song L, Fang H, Tan J, Zheng Y, Yi J. Potential mechanistic roles of Interleukin-33 in rheumatoid arthritis. Int Immunopharmacol. 2023; 123: 110770. DOI: 10.1016/j.intimp.2023.110770

19. Danieli MG, Antonelli E, Piga MA, Claudi I, Palmeri D. et al. Alarmins in autoimmune diseases. Autoimmun Rev. 2022; 21 (9): 103142. DOI: 10.1016/j.autrev.2022.103142

20. Liu R, Wang F, Luo X, Yang F, Gao J. et al. The immunomodulatory of interleukin-33 in rheumatoid arthritis: A systematic review. Clin Immunol. 2024; 265: 110264. DOI: 10.1016/j.clim.2024.110264

21. Tang J, Xia J, Gao H, Jiang R, Xiao L. et al. IL33-induced neutrophil extracellular traps (NETs) mediate a positive feedback loop for synovial inflammation and NET amplification in rheumatoid arthritis. Exp Mol Med. 2024; 56 (12): 2602–2616. DOI: 10.1038/s12276-024-01351-7

22. Rahmati M, Kwesiga MP, Lou J, Tan AL, McDermott MF. Novel targeted therapies for rheumatoid arthritis based on intracellular signalling and immunometabolic changes: a narrative review. Front Biosci (Landmark Ed). 2024; 29 (1): 42. DOI:10.31083/j.fbl2901042

23. Liu R. Shen H, Wang W, Du W, Fu X, et al. IL-33 promotes rheumatoid arthritis progression by enhancing pro-inflammatory macrophage development in the synovial microenvironment. Clin Sci (Lond). 2026; 140 (3): 359–376. DOI: 10.1042/CS20258645

24. Fujimoto S, Niiro H. Pathogenic Role of Cytokines in Rheumatoid Arthritis. J Clin Med. 2025; 14 (18): 6409. DOI: 10.3390/jcm14186409

25. Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2026: S 0003– 4967 (26) 00075-0. DOI: 10.1016/j.ard.2026.01.023

26. Sauve E, Barnabe C. The usual suspects: Established and emerging predictor variables for remission in rheumatoid arthritis. J Rheumatol. 2026; 53 (2): 126–133. DOI: 10.3899/jrheum.2025-0476

27. Nasonov E. L. Advances in pharmacotherapy for immunoinflammatory rheumatic diseases in the 21st century. Terapevticheskii Arkhiv (Ter. Arkh.). 2025; 97 (5): 401–411. (In Russ). DOI: 10.26442/00403660.2025.05.203213


Review

For citations:


Baranov A.A., Lapkina N.A., Shubin L.B., Vorontsova I.M., Chizhov P.A., Lebedev O.V., Buydina T.A., Nikitina E.V., Gorohov I.A. Cytokine clusters in rheumatoid arthritis: pathogenetic parallels. Medical alphabet. 2026;(12):38-44. (In Russ.) https://doi.org/10.33667/2078-5631-2026-12-38-44

Views: 141

JATS XML


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)